Orser Capital Management LLC Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY

Orser Capital Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,544 shares of the biopharmaceutical company’s stock, valued at approximately $704,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in ALNY. Norges Bank bought a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $662,837,000. Holocene Advisors LP acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $194,616,000. Orbis Allan Gray Ltd grew its stake in Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after buying an additional 486,489 shares during the last quarter. Vanguard Group Inc. grew its position in Alnylam Pharmaceuticals by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company’s stock worth $4,336,064,000 after acquiring an additional 240,534 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its stake in shares of Alnylam Pharmaceuticals by 203.2% in the first quarter. Adage Capital Partners GP L.L.C. now owns 282,184 shares of the biopharmaceutical company’s stock valued at $76,195,000 after buying an additional 189,128 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

ALNY has been the subject of several recent research reports. Stifel Nicolaus upped their target price on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Wells Fargo & Company upped their price objective on Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Evercore ISI boosted their price target on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a research report on Thursday, September 11th. Leerink Partners decreased their target price on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research note on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, October 8th. Twenty-three analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $477.44.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $392.10 on Thursday. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. The firm has a market cap of $51.80 billion, a PE ratio of 1,633.75 and a beta of 0.30. The business’s 50 day moving average price is $448.60 and its two-hundred day moving average price is $409.30. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Pushkal Garg sold 3,022 shares of the stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $451.48, for a total transaction of $1,364,372.56. Following the sale, the executive vice president owned 20,221 shares of the company’s stock, valued at approximately $9,129,377.08. This represents a 13.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Tolga Tanguler sold 1,405 shares of the stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $635,130.25. Following the completion of the sale, the executive vice president owned 27,438 shares in the company, valued at $12,403,347.90. This trade represents a 4.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 60,328 shares of company stock valued at $27,288,993. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.